Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Sinocelltech Group's FCF Margin % or its related term are showing as below:
SHSE:688520'
s FCF Margin % Range Over the Past 10 Years
Min: -199593.9 Med: -483.57 Max: -9.97
Current: -37.85
During the past 10 years, the highest FCF Margin % of Sinocelltech Group was -9.97%. The lowest was -199593.90%. And the median was -483.57%.
SHSE:688520's FCF Margin % is ranked better than 58% of 950
companies
in the Biotechnology industry
Industry Median: -79.025
vs SHSE:688520: -37.85
Sinocelltech Group FCF Margin % Related Terms
Sinocelltech Group FCF Margin % Historical Data
* Premium members only.
The historical data trend for Sinocelltech Group's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688520 vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Sinocelltech Group's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinocelltech Group FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sinocelltech Group's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Sinocelltech Group's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinocelltech Group (SHSE:688520) has a FCF Margin % of -55.58% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Sinocelltech Group and its competitors. According to the industry distribution chart, Sinocelltech Group ranks #399 out of 950 companies in the Biotechnology industry, placing it in the top 42%.
Is Sinocelltech Group's FCF Margin % too high?
Sinocelltech Group's current FCF Margin % is -55.58%. Based on the distribution chart, Sinocelltech Group ranks #399 out of 950 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sinocelltech Group has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sinocelltech Group's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sinocelltech Group ranks #399 out of 950 companies for FCF Margin %. This puts Sinocelltech Group in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Sinocelltech Group and its competitors. Sinocelltech Group's current FCF Margin % is -55.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinocelltech Group stock overvalued right now?
Based on GuruFocus' analysis, Sinocelltech Group (SHSE:688520) is currently considered Fairly Valued. The stock's GF Value™ is ¥36.51, compared to a current price of ¥35.23 — trading 3.5% below its estimated fair value. The current FCF Margin % is -55.58%. Sinocelltech Group's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Sinocelltech Group (SHSE:688520), the current FCF Margin % is -55.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinocelltech Group (SHSE:688520) Overvalued in 2026?
Based on GuruFocus' analysis, Sinocelltech Group stock appears to be undervalued.
The current stock price of ¥35.23 is trading 3.5% below its estimated GF Value™ of ¥36.51.
GuruFocus considers Sinocelltech Group to be Fairly Valued.
Key valuation signals for SHSE:688520:
FCF Margin %: -55.58%
GF Value™: ¥36.51 vs. price of ¥35.23 (3.5% below fair value)
No single metric tells the full story. See the SHSE:688520 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sinocelltech Group Ltd is one of Chin's biopharma companies specializing in biologics and vaccines. The company's therapeutic areas include oncology, immunology and inflammation, ophthalmology, and prophylactic vaccines. The company has developed technology platforms in protein expression vectors, cell line development, serum-free medium development, stoichiometrically controlled fed-batch cell culture, process scale-up, and protein purification. The capabilities of the company include stable CHO cell line development, cell banking and certification, serum-free and protein-free culture medium development, fed-batch cell culture process development, optimization, and process scale-up, protein purification development, and large scale production.
54GF Score
Get the complete analysis for SHSE:688520
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688520 has been successfully added to your 
